Home » Norwich Pharmaceuticals Awarded Manufacturer of the Year
Norwich Pharmaceuticals Awarded Manufacturer of the Year
Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has been recognized as Manufacturer of the Year by the Chenango County Chamber of Commerce. The award presentation occurs at a time when Norwich is celebrating 125 years of continuous operation for pharmaceutical manufacturing.
“The Chamber recognizes that managing a manufacturing business in a rural environment can be challenging,” said Steve Craig, president and CEO of the Chenango Chamber. “The continued success and sustainability shown by Norwich Pharmaceuticals indicates an ability to respond to changing market demands and contribute to our local economy.”
Selection criteria for the award included employment growth, increase in sales, contributions to the community, and current and past financial results. Previous award winners include The Mid-York Press, Chentronics Corporation, and Sunrise Family Farms.
“Norwich is honored to receive this important recognition from Commerce Chenango and the member companies of the Chamber,” said Terry Novak, president of Norwich. “We constantly are focused to ensure that the life-saving medications we produce meet high quality standards for our customers, for patients, and also for our local community. Norwich Pharmaceuticals is proud to be a business partner for Chenango County, its businesses and residents.”
Established in 1887, the company has been recognized throughout its history for manufacturing important medications. Now celebrating its 125th anniversary, Norwich Pharmaceuticals has evolved its business model to provide contract development, manufacturing and clinical services for the pharmaceuticals and biotech industries. Most recently, the company was awarded $2 million in Excelsior Jobs Tax Credits by New York Governor Andrew M. Cuomo. Giving back to the community remains a priority of the company and many of its employees are involved in volunteer efforts for the Chenango United Way, Chenango County Relay for Life, Commerce Chenango boards, and more.
About Norwich Pharmaceuticals
Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies 125 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit www.norwichpharma.com for more information.
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
- All news »